Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manav Segal

Allergy & Immunology Wyndmoor, PA Medical Doctor

NPI 1275747636 CMS profile 1055254

8200 Flourtown Avenue, Suite 4, Wyndmoor, PA 19038

Open in the dashboard

General payments

$51,265

88 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manav Segal of Wyndmoor, PA is reported in the CMS Open Payments database as having received $51,265 across 88 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19 1
2024 General $114 6
2023 General $18,075 22
2022 General $17,271 21
2021 General $959 7
2020 General $3,984 6
2019 General $10,843 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manav Segal
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Manav Segal were reported at $19. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Manav Segal Allergy & Immunology median Middle half National median
2019 $10,843 $594 $163–$1,512 $163
2020 $3,984 $426 $106–$1,233 $114
2021 $959 $638 $157–$1,708 $132
2022 $17,271 $790 $205–$1,961 $149
2023 $18,075 $852 $220–$2,147 $160
2024 $114 $865 $203–$2,267 $164
2025 $19 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $42,883 64 payments
  2. Amgen Inc. $7,898 11 payments
  3. GlaxoSmithKline, LLC. $161 4 payments
  4. OptiNose US, Inc. $111 1 payment
  5. Sanofi-Aventis U.S. LLC $65 1 payment
  6. Genzyme Corporation $37 2 payments
  7. Genentech USA, Inc. $28 1 payment
  8. Shire North American Group Inc $25 1 payment
  9. Takeda Pharmaceuticals U.S.A., Inc. $23 1 payment
  10. Novartis Pharmaceuticals Corporation $19 1 payment
  11. Other $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $47,775 35 payments
  2. Food and Beverage $3,416 51 payments
  3. Education $74 2 payments
Products named General payments · program years 2019–2025
  1. TEZSPIRE Respiratory $23,279 27 payments
  2. FASENRA Respiratory $14,506 23 payments
  3. TEZSPIRE Inflammation $7,898 11 payments
  4. FASENRA Respiratory $4,937 10 payments
  5. NUCALA Respiratory $127 2 payments
  6. Xhance $111 1 payment
  7. DUPIXENT Immunology $65 1 payment
  8. TAKHZYRO $48 2 payments
  9. DUPIXENT Immunology $37 2 payments
  10. NUCALA Immunology $34 2 payments
  11. Other $63 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

986

Median for Allergy/ Immunology: 449

Drug cost

$556,694

Median for Allergy/ Immunology: $169,700

Branded share of claims

50.8%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xolair Omalizumab Brand 46 $139,716
Dupixent Pen Dupilumab Brand 28 $103,966
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 32 $93,761
Dupixent Syringe Dupilumab Brand 18 $73,626
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 36 $30,040
Breo Ellipta Fluticasone/Vilanterol Brand 61 $29,372
Spiriva Respimat Tiotropium Bromide Brand 22 $16,749
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 18 $15,315
Epinephrine Generic 45 $10,161
Advair Hfa Fluticasone Propion/Salmeterol Brand 18 $10,125

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$75,508

Medicare's payments for the services billed

Medicare patients

240

Average age 73

Services billed

5,164

180 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 50%
Diabetes 23%
Osteoporosis 21%
Depression 20%
Ischemic heart disease 18%
Cancer 17%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • Amgen Inc. $52
$52 — —
NUCALA
  • GlaxoSmithKline, LLC. $34
$34 — —
Xolair
  • Genentech USA, Inc. $28
$28 46 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

88 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record